Eisai U.S. Alzheimer’s Disease and Brain Health

Are you a U.S. health care professional ready to advance your understanding of diagnosing Alzheimer’s disease (AD)? Sign up for the next ARIA MRI case-based learning session Thursday, October 10, at 1:00 PM ET. A neuroradiologist with advanced amyloid-related imaging abnormalities (ARIA) expertise will delve into cases demonstrating ARIA, severity grading, imaging pitfalls, and differential diagnosis. #AlzheimersDisease #dementia

Early Detection: Recognizing Memory and Cognitive Changes in Alzheimer's Disease "It's important that individuals look out for changes in memory, word finding, and navigation." - Dr. Sharon Cohen, Neurologist and Medical Director, Toronto Memory Program She highlights that individuals experiencing symptoms may be the first to notice, but it's also crucial for family members to be observant, as the affected part of the brain can hinder self-reflection. Dr. Cohen underlines the significance of detecting these changes early, encouraging listeners to be vigilant in recognizing potential symptoms in themselves or their loved ones. “Detecting early changes and not ignoring them is really step one!” The episode provides valuable insights into the early signs of Alzheimer's disease and empowers listeners to be attentive and proactive in seeking support and care if they notice any concerning changes. Let's raise awareness together. Listen and share Rethinking Alzheimer's Disease. #Alzheimers #dementia #dementiacare #caregiving #alzheimersdisease #HealthUNMUTED Eisai US , Eisai U.S. Alzheimer’s Disease and Brain Health https://lnkd.in/eJzFM2Kc

It’s important that participants in Alzheimer’s disease (AD) clinical trials reflect the real-world population of people who are most likely to develop AD. Dung Trinh, MD, Chief Medical Officer at the Healthy Brain Clinic, explains why while highlighting the communities that have historically been underserved in this collaborative video series with Biogen. Learn more about Eisai’s commitment to AD research here: https://ow.ly/J5Ii50ThvwI #AlzheimersDisease #healthequity #neurology

Harald Hampel, MD, PhD, MSc and colleagues, including Suzanne Hendrix and Jeffrey Dage, published an article in Med by Cell Press featuring fluid biomarkers findings across 12 anti-amyloid beta clinical trials. The emerging biomarker data provide evidence on the impact of new therapies on the underlying pathophysiological processes of Alzheimer’s disease, supporting the presence of a disease-modifying effect. Read more:  https://ow.ly/AU0A50TAm5Y   #neurology #AlzheimersDisease #biomarkers #clinicaltrials

On International Day of Older Persons, we’re highlighting neurologists’ crucial role in differentiating between normal aging and cognitive decline in Alzheimer’s disease (AD). We have resources for U.S. health care providers on key steps in assessing cognitive complaints: https://ow.ly/gvWa50TzCCZ #AlzheimersDisease #InternationalDayOfOlderPersons #EndAlz

Positron emission tomography (PET) imaging can provide information about biomarkers of Alzheimer’s disease (AD), including levels and regional distribution of aggregated pathological proteins in the brain. U.S. health care providers can gain a deeper understanding from diagnostic radiologist and neuroradiologist Ana M. Franceschi, MD PhD: https://ow.ly/5b2K50TwxGk #AlzheimersDisease #EndAlz #neurology

Today, our incredible team at Eisai India participated in the Alzheimer's Day Memory Walk on Beach Road, Vizag, India, raising awareness and support for those affected by Alzheimer's. Each step we take is a step toward a brighter future, honoring the memories of loved ones and stand in solidarity with their families. Together, we're making strides to help find a cure and bring hope to millions. #Alzheimer'sAwarness #TogetherWeRemember #EndAlz #OneEisai

We were honored to host Cheryl Ricci-Francione, Executive Director, and Lori Balog, Health Systems Director, from the Alzheimer's Association®. They spoke about the organization's Walk to End Alzheimer’s and its impactful programs and resources. We also had the privilege of hearing from Allison Roberts about caring for her mother, Henrietta, who lived with #Alzheimers disease. Eisai remains deeply committed to the Alzheimer's disease community, supporting caregivers and advancing research to improve the lives of those affected. #LifeAtEisai

There are key considerations when analyzing Alzheimer’s disease (AD) clinical trials. Dung Trinh, MD, Chief Medical Officer at the Healthy Brain Clinic, details the criteria physicians should look for in this collaborative video series with Biogen. Visit our website to learn more about Eisai’s approach to AD research: https://ow.ly/q0vy50Thv9S #AlzheimersDisease #earlyAD #ClinicalTrials

We're thrilled to highlight a new article by two of our Blood-based Biomarker Workgroup Members, Suzanne Schindler and Daryl Rhys Jones, PhD, published in Nature Portfolio: "Blood Tests for Alzheimer’s Disease in the Era of Anti-Amyloid Therapies." Alzheimer’s disease remains a major public health challenge, affecting millions worldwide—patients, caregivers, and communities alike. The article explores the crucial role blood tests play in diagnosing Alzheimer’s, especially as anti-amyloid and anti-tau therapies evolve. For over 40 years, Eisai has been at the forefront of AD drug discovery, from symptomatic treatments in the 1980s to cutting-edge antibody development today. Their commitment goes beyond treatments, advancing diagnostic tools like blood biomarkers (BBMs) to ensure timely, accurate diagnosis. Check out the full article below! https://lnkd.in/gGrxWsfT #Alzheimers #BloodTests #Neuroscience #HealthcareInnovation #Diagnostics #BBM #AntiAmyloid #AlzheimersAwareness #HealthTech